It has been billed as one of the biggest medical discoveries in recent history. The shingles vaccine, originally designed to protect against the agonising blister condition, appears to also ward off dementia.
Compelling research has shown that the jab can slash the risk of the incurable brain disease by as much as 20 per cent and, according to recent analysis, by 50 per cent for vascular dementia – one of the most common types.
The pharmaceutical company behind the jab, GSK, is now exploring whether it could be officially classed as a dementia vaccine. Already, more Britons are lining up for it.
To provide well-rounded coverage and a breadth of insight across various events, we rely on contributions from several staff writers, each bringing their own area of expertise to our publication.